financetom
Business
financetom
/
Business
/
Braze Swings to Fiscal Q3 Non-GAAP Earnings as Revenue Rises; Fiscal 2025 Outlook Raised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Braze Swings to Fiscal Q3 Non-GAAP Earnings as Revenue Rises; Fiscal 2025 Outlook Raised
Dec 9, 2024 2:11 PM

04:48 PM EST, 12/09/2024 (MT Newswires) -- Braze (BRZE) reported late Monday its fiscal Q3 swung to non-GAAP earnings of $0.02 per diluted share from a loss of $0.05 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.01.

Revenue for the quarter ended Oct. 31 was $152.1 million, up from $124.0 million a year earlier.

Analysts surveyed by FactSet expected $148.2 million.

The company said it expects fiscal Q4 non-GAAP net income per diluted share of $0.05 to $0.06 on revenue of $155 million to $156 million. Analysts surveyed by FactSet expect non-GAAP EPS of $0.04 on revenue of $155.2 million.

For fiscal 2025, Braze now expects non-GAAP net income per diluted share of $0.10 to $0.11 on revenue of $588 million to $589 million. It previously expected non-GAAP EPS of $0.06 to $0.07 on revenue of $582.5 million to $585.5 million. Analysts surveyed by FactSet are looking for non-GAAP EPS of $0.07 on revenue of $584.4 million.

Shares of the company were down 6.4% in recent after-hours activity.

Price: 39.11, Change: -2.69, Percent Change: -6.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EssilorLuxottica receives FDA clearance for its Nuance audio glasses
EssilorLuxottica receives FDA clearance for its Nuance audio glasses
Feb 3, 2025
ROME (Reuters) - EssilorLuxottica said on Monday it received a green light from the U.S. Food and Drug Administration (FDA) for its over-the-counter Nuance audio glasses. Nuance - which pairs hearing solutions with prescription glasses - will be available in the U.S. and in Italy in the first quarter of the year and in other European countries, including France, Germany...
Alkermes Insider Sold Shares Worth $3,234,382, According to a Recent SEC Filing
Alkermes Insider Sold Shares Worth $3,234,382, According to a Recent SEC Filing
Feb 3, 2025
03:12 AM EST, 02/03/2025 (MT Newswires) -- Craig C. Hopkinson, Executive Vice President, Research & Development, Chief Medical Officer, on January 30, 2025, sold 100,918 ordinary shares in Alkermes ( ALKS ) for $3,234,382. Following the Form 4 filing with the SEC, Hopkinson has control over a total of 44,290 shares of the company, with 44,290 shares held directly. SEC...
Tempus AI Insider Sold Shares Worth $13,278,632, According to a Recent SEC Filing
Tempus AI Insider Sold Shares Worth $13,278,632, According to a Recent SEC Filing
Feb 3, 2025
03:10 AM EST, 02/03/2025 (MT Newswires) -- Eric P Lefkofsky, 10% Owner, Director, Chief Executive Officer and Chairman, on January 29, 2025, sold 238,800 Class A common shares in Tempus AI ( TEM ) for $13,278,632. Following the Form 4 filing with the SEC, Lefkofsky has control over a total of 48,757,318 shares of the company, with 5,532,987 shares held...
Natera Insider Sold Shares Worth $2,269,928, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $2,269,928, According to a Recent SEC Filing
Feb 3, 2025
03:09 AM EST, 02/03/2025 (MT Newswires) -- Steven Leonard Chapman, Director, Chief Executive Officer and President, on January 29, 2025, sold 13,685 common shares in Natera ( NTRA ) for $2,269,928. Following the Form 4 filing with the SEC, Chapman has control over a total of 253,944 shares of the company, with 253,944 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1604821/000141588925002621/xslF345X05/form4-01312025_090101.xml ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved